Targeting the interactions of activated CaN with specific substrates in cancer cells, without affecting the normal immune function of CaN, may effectively inhibit the growth of cancer cells, leading to the establishment of new tumor-specific therapies. The gene discussed is NUP214; the disease is neoplasm.